WHAT SIXTY YEARS OF RESEARCH SAYS ABOUT THE EFFECTIVENESS OF PATIENT EDUCATION ON HEALTH: A SECOND ORDER META-ANALYSIS

2021 ◽  
pp. 1-61
Author(s):  
Bianca A. Simonsmeier ◽  
Maja Flaig ◽  
Thomas Simacek ◽  
Michael Schneider
2016 ◽  
Vol 68 (3) ◽  
pp. 422-433 ◽  
Author(s):  
Daniel J. Devoe ◽  
Ben Wong ◽  
Matthew T. James ◽  
Pietro Ravani ◽  
Matthew J. Oliver ◽  
...  

2020 ◽  
pp. bmjqs-2020-010927
Author(s):  
Sara Daliri ◽  
Samira Boujarfi ◽  
Asma el Mokaddam ◽  
Wilma J M Scholte op Reimer ◽  
Gerben ter Riet ◽  
...  

BackgroundHarm due to medications is common during the transition from hospital to home. Approaches that seek to prevent harm often involve isolated medication-related interventions and show conflicting results. However, until now, no review has focused on the effect of intervention components delivered both in hospital and following discharge from hospital to home.ObjectiveTo examine effects of medication-related interventions on hospital readmissions, medication-related problems (MRPs), medication adherence and mortality.MethodsFor this systematic review and meta-analysis, we searched the PubMed, Embase, CINAHL and CENTRAL databases without language restrictions. Citations of included articles were checked through Web of Science and Scopus from inception to 20 June 2019. We included prospective studies that examined effects of medication-related interventions delivered both in hospital and following discharge from hospital to home compared with usual care. Three authors independently extracted data and assessed study quality in pairs.ResultsFourteen original studies were included, comprising 8182 patients. Interventions consisted mainly of patient education and medication reconciliation in the hospital, and patient education following discharge. Nine studies were included in the meta-analysis; compared with usual care (n=3376 patients), medication-related interventions (n=1820 patients) reduced hospital readmissions by 3.8 percentage points within 30 days of discharge (number needed to treat=27, risk ratio (RR) 0.79 (95% CI 0.65 to 0.96)). Meta-regression analysis suggested that readmission rates were reduced by 17% per additional intervention component (RR 0.83 (95% Cl 0.75 to 0.91)). Medication adherence and MRPs may be improved. Effects on mortality were unclear.ConclusionsStudied medication-related interventions reduce all-cause hospital readmissions within 30 days. The treatment effect appears to increase with higher intervention intensities. More evidence is needed for recommendations on adherence, mortality and MRPs.


2019 ◽  
Vol 82 ◽  
pp. 103848 ◽  
Author(s):  
Yimin He ◽  
M. Brent Donnellan ◽  
Anjelica M. Mendoza

2019 ◽  
Vol 25 (8) ◽  
pp. 1945-1967 ◽  
Author(s):  
Eve M Segal ◽  
Jill Bates ◽  
Sara L Fleszar ◽  
Lisa M Holle ◽  
Julie Kennerly-Shah ◽  
...  

IntroductionAlthough many oncology pharmacists are embedded members within the healthcare team, data documenting their contributions to optimal patient outcomes are growing. The purpose of this paper is to demonstrate the value of the oncology pharmacist within the healthcare team and describe the knowledge, skills, and functions of the oncology pharmacist.MethodsA systematic literature review of articles that were published on PubMed between January 1951 and October 2018 was completed. Identified abstracts were reviewed and included if they focused on measuring the value or impact of the oncology pharmacist on provider/patient satisfaction, improvement of medication safety, improvement of quality/clinical care outcomes, economics, and intervention acceptance. Review articles, meta-analysis, and studies not evaluating oncology pharmacist activities were excluded. Studies were thematically coded into four themes (clinical care, patient education, informatics, and cost savings) by 10 oncology pharmacists.ResultsFour-hundred twenty-two articles were identified, in which 66 articles met inclusion criteria for this review. The selected literature included 27 interventional and 38 descriptive studies. The value of the oncology pharmacist was demonstrated by published articles in four key themes: clinical care, patient education, informatics, and cost savings.ConclusionWith an expected shortage of oncology physicians and the ongoing development of complex oncology therapies, the board-certified oncology pharmacist is well suited to serve as a physician extender alongside nurse practitioners and/or physician assistants as the medication expert on the oncology care team. The demonstrated value of the oncology pharmacist supports their role as frontline providers of patient care.


1997 ◽  
Vol 32 (3) ◽  
pp. 157-173 ◽  
Author(s):  
Patricia Dolan Mullen ◽  
Denise G Simons-Morton ◽  
Gilbert Ramı́rez ◽  
Ralph F Frankowski ◽  
Lawrence W Green ◽  
...  

2004 ◽  
Vol 52 (1) ◽  
pp. 97-105 ◽  
Author(s):  
Shelley E Ellis ◽  
Theodore Speroff ◽  
Robert S Dittus ◽  
Anne Brown ◽  
James W Pichert ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document